Olfen Patch (Diclofenac Sodium)

Diclofenac sodium, the active ingredient in Olfen Patch, is a non‑steroidal anti‑inflammatory drug presented as a topical patch for transdermal use. It is employed to relieve pain and reduce inflammation associated with musculoskeletal conditions in adults.

GNH USA supplies Olfen Patch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac sodium is an NSAID that acts on inflammatory pathways to manage pain and swelling. - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: alleviates joint inflammation and stiffness. - Acute musculoskeletal injury: provides localized pain relief and decreases swelling.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Skin irritation at the application site: redness or itching. - Localized rash: mild erythema. - Dry skin: occasional peeling. - Pruritus: mild itching sensation. - Sensation of warmth: mild burning feeling.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Systemic hypersensitivity: anaphylaxis or angio‑edema. - Cardiovascular events: increased risk of heart attack or stroke. - Gastrointestinal ulceration: bleeding or perforation. - Hepatic injury: elevated liver enzymes or hepatitis.

When using Olfen Patch, consider the following safety measures: - Contraindications: avoid if you have known allergy to diclofenac or other NSAIDs. - Cardiovascular risk: use with caution if you have a history of heart disease. - Gastrointestinal caution: monitor for signs of ulcer or bleeding. - Skin integrity: apply to intact, non‑irritated skin only. - Pregnancy and lactation: consult a healthcare professional before use. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Diclofenac sodium may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants: increased bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): heightened bleeding tendency. - ACE inhibitors/ARBs: may reduce renal function.

Moderate Interactions (Monitor Closely): - Diuretics: potential for reduced kidney perfusion. - Lithium: possible increase in serum lithium levels. - Methotrexate: enhanced toxicity risk.